Malignant Head and Neck Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Exploiting the head and neck cancer oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets.
|
23847349 |
2013 |
Malignant Head and Neck Neoplasm
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, MSC-CM promoted the expression of POSTN and POSTN promoted HNC progression through the activation of the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway.
|
29284199 |
2018 |
Malignant Head and Neck Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.
|
23619167 |
2013 |
Malignant Head and Neck Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies.
|
24219320 |
2015 |
Malignant Head and Neck Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings reveal a new mechanism by which EGFR/PI3K/Akt/mTOR signaling promotes head and neck cancer progression and underscores the need for developing a therapeutic strategy for targeting IKK/NF-κB either as a single agent or in combination with cisplatin in head and neck cancer.
|
26895469 |
2016 |
Malignant Head and Neck Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Disruption of IQGAP1-scaffolded PI3K/AKT signaling reduced HNC cell survival.
|
31597661 |
2020 |
Malignant Head and Neck Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
|
31785230 |
2020 |
Malignant Head and Neck Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found that PI3K regulatory subunit p85 was predominantly phosphorylated in radioresistant head and neck cancer cell line (HN31), which showed resistance to PI3K inhibitors.
|
29496059 |
2018 |
Malignant Head and Neck Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of the PI3K/Akt pathway decreases hypoxia within SQ20B human head and neck cancer xenografts.
|
25995437 |
2015 |
Malignant Head and Neck Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer.
|
28197389 |
2017 |
Malignant Head and Neck Neoplasm
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Computational analysis indicated that miR-296-3p targeted PTEN, which regulates the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway and PTEN is involved in the carcinogenesis of SCC. miR-296-3p directly regulated PTEN expression in head and neck cancer cells, with PTEN protein levels decreased in 4/19 the SCCs (21.0%), as compared with those in the IPs (76.4%).
|
28693263 |
2017 |
Malignant Head and Neck Neoplasm
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These observations suggest that TrkB is a promising target for future intervention strategies to prevent tumor metastasis, EMT program in laryngeal cancer.What is already known about this subject?• Cancer of the larynx is one of the most common types of head and neck cancer.• The survival rate of advanced laryngeal cancer is only 30 to 40%.• The tropomyosin-related kinase B receptor (TrkB), together with TrkA and TrkC, are neurotrophin receptors regulating the proliferation and differentiation of neuronal cells.What are the new findings?• TrkB are overexpressed in laryngeal cancer.• TrkB signaling is involved in tumorigenicity of laryngeal cancer.• TrkB acts as a key regulator of the PI3K/AKT signal pathway-mediated tumor metastasis.How might these results change the focus of research or clinical practice?• These observations suggest that TrkB is a promising target for future intervention strategies to prevent tumor metastasis, EMT program in laryngeal cancer.
|
29312563 |
2017 |
Malignant Head and Neck Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.
|
29440171 |
2018 |
Malignant Head and Neck Neoplasm
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
|
23640975 |
2013 |
Malignant Head and Neck Neoplasm
|
0.400 |
CausalMutation
|
disease |
CGI |
|
|
|